Equities research analysts predict that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will post $522.51 million in sales for the current quarter, according to Zacks. Eight analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $515.40 million and the highest estimate coming in at $527.00 million. Jazz Pharmaceuticals reported sales of $469.37 million in the same quarter last year, which indicates a positive year over year growth rate of 11.3%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $2.11 billion for the current year, with estimates ranging from $2.09 billion to $2.15 billion. For the next financial year, analysts forecast that the business will report sales of $2.34 billion, with estimates ranging from $2.26 billion to $2.39 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm had revenue of $534.13 million for the quarter, compared to analyst estimates of $507.23 million. During the same quarter in the prior year, the firm posted $3.49 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis.
Several equities analysts have weighed in on the company. Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 3rd. Oppenheimer set a $176.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 26th. Sanford C. Bernstein reissued a “market perform” rating and issued a $150.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, October 14th. Mizuho set a $148.00 target price on Jazz Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, July 3rd. Finally, HC Wainwright reissued a “hold” rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. Jazz Pharmaceuticals has a consensus rating of “Hold” and an average target price of $167.20.
NASDAQ:JAZZ opened at $119.65 on Friday. Jazz Pharmaceuticals has a 1-year low of $113.52 and a 1-year high of $165.66. The business’s 50-day moving average price is $126.27 and its two-hundred day moving average price is $133.10. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $6.86 billion, a price-to-earnings ratio of 9.78, a PEG ratio of 1.49 and a beta of 1.11.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total value of $65,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Catherine A. Sohn sold 726 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the completion of the sale, the director now owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The disclosure for this sale can be found here. Insiders sold 5,597 shares of company stock valued at $764,057 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 2.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 457,226 shares of the specialty pharmaceutical company’s stock worth $65,183,000 after buying an additional 9,797 shares in the last quarter. HBK Sorce Advisory LLC bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $324,000. CENTRAL TRUST Co grew its holdings in shares of Jazz Pharmaceuticals by 256.4% during the second quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock worth $210,000 after buying an additional 1,095 shares in the last quarter. Chicago Equity Partners LLC grew its holdings in shares of Jazz Pharmaceuticals by 152.4% during the second quarter. Chicago Equity Partners LLC now owns 16,760 shares of the specialty pharmaceutical company’s stock worth $2,389,000 after buying an additional 10,120 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $1,626,000. Institutional investors and hedge funds own 87.54% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: How does new data get added to a blockchain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.